Cellectar Biosciences, Inc.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $13.2M | $23.3M | $9.6M | $19.9M | $35.7M | $57.2M | $10.6M | $13.3M |
| Accounts Receivable | — | — | — | — | — | — | — | — |
| Inventory | — | — | — | — | — | — | — | — |
| Total Current Assets | $14.0M | $24.3M | $10.5M | $20.5M | $36.6M | $57.9M | $11.4M | $14.0M |
| Property, Plant & Equipment | $549.4K | $757.1K | $1.1M | $418.6K | $344.5K | $356.0K | $435.1K | $543.3K |
| Goodwill | — | — | — | — | — | — | $0 | $0 |
| Intangible Assets (Excl. Goodwill) | — | — | — | — | — | — | — | — |
| Total Assets | $15.0M | $25.5M | $12.1M | $21.6M | $37.2M | $58.7M | $12.3M | $15.1M |
| Liabilities | ||||||||
| Accounts Payable | $1.4M | $4.1M | $5.6M | $2.6M | $1.4M | $1.4M | $1.3M | $612.0K |
| Total Current Liabilities | $4.7M | $9.4M | $25.4M | $11.5M | $4.0M | $3.6M | $2.8M | $1.6M |
| Long-Term Debt | — | — | — | — | — | — | — | — |
| Total Liabilities | $5.1M | $9.8M | $25.9M | $12.1M | $4.2M | $3.9M | $3.2M | $1.8M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-269.1M | $-247.3M | $-202.8M | $-160.0M | $-150.9M | $-126.8M | $-111.7M | $-97.6M |
| Total Stockholders' Equity | $8.5M | $14.3M | $-15.2M | $8.2M | $29.1M | $54.8M | $9.1M | $13.3M |